ClinicalTrials.gg
RecruitingNCT07361497Updated Nov 5, 2026

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

A Phase 3 interventional study of Pumitamig and Durvalumab in Non-small Cell Lung Cancer (NSCLC), sponsored by Bristol-Myers Squibb. Recruiting at 259 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 5, 2026Site recruiting status changedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
850
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing pumitamig in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 13 under way, 3 of them phase 3. pumitamig · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
4th of 13
850 · median 594
Started
2026
with 4 others
Phase 3
2 of 13
2 open now
Primary completion
2030-09
later than 9 of 12 live
Registered
9th of 13
by date
Lead sponsor
5 of 13
Bristol-Myers Squibb

Among the 13 studies testing pumitamig in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by planned enrollment, is one of 5 that started in 2026, is one of 2 in phase 3, reaches primary completion later than 9 of the 12 other live ones, and was the 9th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

13 of the 13 studies testing pumitamig in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About pumitamig

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing pumitamig in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)

03

Conditions studied

  • Non-small Cell Lung Cancer (NSCLC)

Keywords

  • Pumitamig
  • Locally advanced
  • Unresectable
  • Stage 3 Non-small Cell Lung Cancer (NSCLC)
  • CA2660001
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a - or cytologically-confirmed diagnoses of non-small cell lung cancer (NSCLC) with unresectable Stage III disease.
  • Participants must have received at least 2 cycles of platinum-based concurrent chemoradiotherapy (a total dose of radiation of at least 54 Gy).
  • Participants must have no progressive disease (PD) following treatment with concurrent chemoradiotherapy (CCRT).
  • Participants must have an (ECOG) performance status (PS) score of 0 or 1.

Exclusion criteria

Exclusion Criteria

  • Participants with non-squamous histology must not have documented Epidermal Growth Factor Receptor (EGFR) and anaplastic lymphoma kinase (ALK) rearrangements.
  • Participants must not have an active disease.
  • Participants must not have significant cardiovascular impairment such as uncontrolled hypertension (despite optimal medical treatment), congestive heart failure, active coronary disease (within 6 months prior to randomization), ventricular arrhythmias, major thrombotic or embolic events or major hemorrhagic events within 6 months prior to randomization, or significant risk of pulmonary hemorrhage.
  • Participants must not have advanced/ lung disease (within 6 months prior to randomization) or history of interstitial lung disease (ILD) or pneumonitis requiring treatment with systemic (≥ Grade 2), or current or suspected ILD or pneumonitis.
  • Participants must not have any prior anticancer therapy (outside of CCRT) for locally advanced Stage III disease.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
850 participants (estimated)

Study arms

  • Experimental
    Arm A

    Drug: Pumitamig

  • Active comparator
    Arm B

    Drug: Durvalumab

Interventions

  • Specified dose on specified days

    Also known as: BMS-986545

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) by blinded independent central review (BICR) (per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1)

    Time frame: Up to 3 years

Secondary outcomes

  1. Overall survival (OS)

    Time frame: Up to approximately 9 years

  2. PFS by investigator (per RECIST v1.1)

    Time frame: Up to 3 years

  3. Objective response (OR) by BICR (per RECIST v1.1)

    Time frame: Up to 3 years

  4. Disease control rate (DCR) by BICR (per RECIST v1.1)

    Time frame: Up to 3 years

  5. Duration of response (DOR) by BICR (per RECIST v1.1)

    Time frame: Up to 3 years

  6. Time to Response (TTR) by BICR (per RECIST v1.1)

    Time frame: Up to 3 years

07

Study locations

201 of 259 sites recruiting
  • Southern Cancer Center Pc
    Daphne, Alabama 36526, United States
    Recruiting
    • Michael Meshad, Site 0898 · Contact111-111-1111
  • Intermountain Health Cancer Center Lutheran Hospital
    Golden, Colorado 80401, United States
    Recruiting
    • Karng Log, Site 0585 · Contact303-403-7333
  • Medical Oncology Hematology Consultants, PA
    Newark, Delaware 19713, United States
    Recruiting
    • Jamal Misleh, Site 0896 · Contact302-366-1200
  • Local Institution - 0711
    Ocala, Florida 34474, United States
    Not yet recruiting
    • Site 0711 · Contact
  • Florida Clinical Trials Group
    Tamarac, Florida 33321, United States
    Recruiting
    • Chintan Gandhi, Site 0935 · Contact561-447-0614
  • Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital
    Marietta, Georgia 30060, United States
    Recruiting
    • Walid Shaib, Site 0756 · Contact770-281-5124
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
    Recruiting
    • Everett Vokes, Site 0398 · Contact773-503-0732
  • Endeavor Health
    Evanston, Illinois 60201, United States
    Recruiting
    • Dhruv Bansal, Site 0850 · Contact847-570-2112
  • Illinois Cancer Care
    Peoria, Illinois 61615, United States
    Recruiting
    • Srinivas Jujjavarapu, Site 0897 · Contact309-243-3000
  • Fort Wayne Medical Oncology and Hematology
    Fort Wayne, Indiana 46804, United States
    Recruiting
    • Ahad Sadiq, Site 0317 · Contact260-436-0800
  • University of Kentucky Chandler Medical Center
    Lexington, Kentucky 40536, United States
    Recruiting
    • Zhonglin Hao, Site 0656 · Contact859-218-6704
  • Local Institution - 0603
    Boston, Massachusetts 02114-2621, United States
    Not yet recruiting
    • Site 0603 · Contact
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
    Recruiting
    • Khalil Choucair, Site 0419 · Contact
  • Minnesota Oncology Hematology
    Maple Grove, Minnesota 55369, United States
    Recruiting
    • Daniel Mundt, Site 0322 · Contact
  • Allina Health Cancer Institute - Abbott Northwestern Hospital
    Minneapolis, Minnesota 55407, United States
    Recruiting
    • Charlene Fares, Site 0142 · Contact651-241-7025
  • Missouri Cancer Associates
    Columbia, Missouri 65201, United States
    Recruiting
    • Caleb Smith, Site 0900 · Contact
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Mark Awad, Site 0606 · Contact
  • Local Institution - 0339
    Westbury, New York 11590, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Optum Medical Care, PC
    Westbury, New York 11590, United States
    Recruiting
    • Jonathan Goldberg, Site 0909 · Contact914-242-2991
  • Novant Health Pharmacy Oncology Specialists
    Winston-Salem, North Carolina 27103, United States
    Recruiting
    • Garrett Sherwood, Site 0493 · Contact336-209-0239
  • Akron General Medical Center
    Akron, Ohio 44302, United States
    Recruiting
    • James Stevenson, Site 0923 · Contact216-636-6888
  • The Christ Hospital
    Cincinnati, Ohio 45219, United States
    Recruiting
    • Brittaney-Belle Gordon, Site 0412 · Contact513-321-4333
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
    Recruiting
    • Matthew Mirsky, Site 0359 · Contact301-980-8969
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
    Recruiting
    • James Stevenson, Site 0597 · Contact216-636-6888
  • Cleveland Clinic - Hillcrest Hospital
    Mayfield Heights, Ohio 44124, United States
    Recruiting
    • James Stevenson, Site 0924 · Contact216-636-6888
  • Oncology Associates Of Oregon, Pc
    Eugene, Oregon 97401, United States
    Recruiting
    • Bo Wang, Site 0895 · Contact541-683-5001
  • Northwest Cancer Specialists, P.C.
    Happy Valley, Oregon 97015, United States
    Recruiting
    • Anthony Van Ho, Site 0302 · Contact503-885-5411
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
    Recruiting
    • Melissa Johnson, Site 0240 · Contact615-329-7274
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
    Recruiting
    • Wade Iams, Site 0480 · Contact615-322-4967
  • Texas Oncology - Amarillo Cancer Center
    Amarillo, Texas 79124, United States
    Recruiting
    • Pankaj Khandelwal, Site 0908 · Contact000-000-0000
  • Texas Oncology-Austin Central
    Austin, Texas 78731, United States
    Recruiting
    • James Uyeki, Site 0857 · Contact512-427-9400
  • Texas Oncology
    Denton, Texas 76210, United States
    Recruiting
    • Kartik Konduri, Site 0894 · Contact214-370-1000
  • The Center For Cancer And Blood Disorders
    Fort Worth, Texas 76104, United States
    Recruiting
    • Ray Page, Site 0811 · Contact817-759-7000
  • The University of Texas-MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • Tina Cascone, Site 0596 · Contact713-792-6363
  • Texas Oncology - San Antonio Medical Center
    San Antonio, Texas 78229, United States
    Recruiting
    • Krishna Alluri, Site 0902 · Contact210-656-7177
  • Texas Oncology - Northeast Texas
    Tyler, Texas 75702, United States
    Recruiting
    • Sarah Wang, Site 0899 · Contact903-579-9800
  • Blue Ridge Cancer Care
    Christiansburg, Virginia 24073, United States
    Recruiting
    • Jerome Goldschmidt, Site 0133 · Contact540-381-5291
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
    Recruiting
    • John Paschold, Site 0250 · Contact
  • Instituto Argentino De Diagnostico Y Tratamiento IADT
    Buenas Aires, Buenos Aires C1049AAG, Argentina
    Recruiting
    • Juan Cundom, Site 0093 · Contact(+54911)4162-5353
  • Investigaciones Oncologicas C Colon SA
    Mar del Plata, Buenos Aires 7600, Argentina
    Recruiting
    • Ignacio Casarini, Site 0082 · Contact+5492235937663
  • Hospital Privado Universitario de Córdoba
    Córdoba, Córdoba Province 5016, Argentina
    Recruiting
    • Jeremias Sierra, Site 0313 · Contact543514862400
  • Sanatorio Parque Rosario
    Rosario, Santa Fe Province 2000, Argentina
    Recruiting
    • Gaston Martinengo, Site 0097 · Contact5493416955611
  • Instituto Medico Especializado Alexander Fleming
    Buenos Aires, 1426, Argentina
    Recruiting
    • Claudio Martin, Site 0094 · Contact+541132218900
  • Clinica Adventista Belgrano
    Buenos Aires, 1430, Argentina
    Recruiting
    • Aldo Perfetti, Site 0078 · Contact5491132682903
  • Hospital Italiano de Buenos Aires
    Buenos Aires, C1199ABB, Argentina
    Recruiting
    • Yamila Ferreira, Site 0761 · Contact11-49590200ext8159
  • Instituto de Investigaciones Clínicas Córdoba S.A.
    Córdoba, X5000, Argentina
    Recruiting
    • Nicolas Castagneris, Site 0608 · Contact549351368119
  • Gosford Hospital
    Gosford, New South Wales 2250, Australia
    Recruiting
    • Matthew Chan, Site 0456 · Contact+61243209890
  • Nepean Hospital
    Penrith, New South Wales 2750, Australia
    Recruiting
    • Deme Karikios, Site 0446 · Contact(02) 4734 1751
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
    Recruiting
    • Adnan Nagrial, Site 0451 · Contact0288905200
  • Lyell McEwin Hospital
    Elizabeth Vale, South Australia 5112, Australia
    Recruiting
    • Joanne Tang, Site 0448 · Contact08 7117 7265
  • Grampians Health
    Ballarat Central, Victoria 3350, Australia
    Recruiting
    • Wasek Faisal, Site 0442 · Contact61(03)53208500
  • Northern Hospital
    Epping, Victoria 3076, Australia
    Recruiting
    • Vishal Boolell, Site 0458 · Contact(03) 9485 9068
  • Joondalup Health Campus
    Joondalup, Western Australia 6027, Australia
    Recruiting
    • Arman Hasani, Site 0476 · Contact+61 8 9400 9897
  • Universitätsklinik Innsbruck
    Innsbruck, 6020, Austria
    Recruiting
    • Andreas Pircher, Site 0190 · Contact4351250483584
  • Ordensklinikum Linz GmbH Elisabethinen
    Linz, 4020, Austria
    Recruiting
    • Dominik Maurer, Site 0192 · Contact4373276764414
  • Medizinische Universitaet Wien/AKH
    Vienna, 1090, Austria
    Recruiting
    • Thorsten Fuereder, Site 0207 · Contact4314040044450
  • Local Institution - 0122
    Anderlecht, Bruxelles-Capitale, Région de 1070, Belgium
    Not yet recruiting
    • Site 0122 · Contact
  • Grand Hôpital de Charleroi
    Charleroi, Hainaut 6060, Belgium
    Recruiting
    • Benoit Colinet, Site 0111 · Contact+32.60.11.90.73
  • Ziekenhuis Oost-Limburg, Campus St.-Jan
    Genk, Limburg 3600, Belgium
    Recruiting
    • Maarten Criel, Site 0714 · Contact+3289808260
  • UZ Gent
    Ghent, Oost-Vlaanderen 9000, Belgium
    Recruiting
    • Veerle Surmont, Site 0120 · Contact32933229500
  • VITAZ
    Sint-Niklaas, Oost-Vlaanderen B-9100, Belgium
    Recruiting
    • Koenraad Deschepper, Site 0117 · Contact3237602327
  • UZ Leuven
    Leuven, Vlaams-Brabant 3000, Belgium
    Recruiting
    • christophe Dooms, Site 0116 · Contact003216340961
  • Algemeen Ziekenhuis klina
    Brasschaat, 2930, Belgium
    Recruiting
    • Vincent Geldhof, Site 0906 · Contact+3234368061
  • Vencer Centro de Pesquisa LTDA
    Teresina, Piauí 64049-200, Brazil
    Recruiting
    • CLAUDIO ROCHA, Site 0615 · Contact5586999007799
  • Liga Norte Riograndense Contra o Câncer
    Natal, Rio Grande do Norte 59062-000, Brazil
    Recruiting
    • Joilda Rego, Site 0498 · Contact558440095595
  • Hospital de Clinicas de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90035-903, Brazil
    Recruiting
    • Tiago Heinen, Site 0619 · Contact555133598619
  • Fundação Pio XII - Hospital de Câncer de Barretos
    Barretos, São Paulo 14784400, Brazil
    Recruiting
    • Josiane Dias, Site 0535 · Contact17996782301
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto
    São José do Rio Preto, São Paulo 15090-000, Brazil
    Recruiting
    • JOÃO SOLER, Site 0538 · Contact551732015054
  • Icesp - Instituto Do Câncer Do Estado de São Paulo
    São Paulo, 01246-000, Brazil
    Recruiting
    • Fernanda Fujiki, Site 0912 · Contact+551138932615
  • Multiprofile Hospital for Active Treatment - Haskovo AD
    Haskovo, 6304, Bulgaria
    Recruiting
    • Stoil Boychev, Site 0736 · Contact+359889214157
  • Complex Oncology Center - Ruse EOOD
    Rousse, 7002, Bulgaria
    Recruiting
    • Nikolay Nikolaev, Site 0551 · Contact0887098616
  • "Sveta Ekaterina" Hospital
    Sofia, 1431, Bulgaria
    Recruiting
    • Galina Kurteva, Site 0826 · Contact+359887623916
  • University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna - ISUL EAD
    Sofia, 1527, Bulgaria
    Recruiting
    • Kremena Vasileva, Site 0732 · Contact
  • Diagnostic and Consultative Center Convex
    Sofia, 1680, Bulgaria
    Recruiting
    • Petya Balikova, Site 0838 · Contact+359 893582321
  • The Ottawa Hospital - General Campus
    Ottawa, Ontario K1H 8L6, Canada
    Recruiting
    • Paul Wheatley-Price, Site 0337 · Contact613737770070175
  • St. Marys Hospital Center
    Montreal, Quebec H3T 1M5, Canada
    Recruiting
    • Adrian Langleben, Site 0644 · Contact514-345-3511-3793
  • IUCPQ
    Québec, G1V 4G5, Canada
    Recruiting
    • Maude Dubé-Pelletier, Site 0682 · Contact418-656-8711
  • Bradford Hill Norte
    Antofagasta, AN 1240000, Chile
    Recruiting
    • Angela Estay, Site 0910 · Contact56994198125
  • Centro de Oncología de Precisión
    Las Condes, Arica y Parinacota Region 7560908, Chile
    Recruiting
    • Pamela Salman Boghikian, Site 0855 · Contact
  • FALP
    Santiago, Santiago Metropolitan 7500921, Chile
    Recruiting
    • Christian Caglevic, Site 0478 · Contact56224457254
  • Bradfordhill
    Santiago, Santiago Metropolitan 8420383, Chile
    Recruiting
    • Carlos Rojas, Site 0077 · Contact+56998744662
  • Oncocentro APYS - Centro de Atencion Medica Oncologica Integral
    Viña del Mar, Valparaiso 2520612, Chile
    Recruiting
    • Alejandro Acevedo Gaete, Site 0328 · Contact+56992369820
  • Beijing Cancer hospital
    Beijing, Beijing Municipality 100142, China
    Recruiting
    • Anhui Shi, Site 0754 · Contact8613901136511
  • Chongqing University Cancer Hospital
    Chongqing, Chongqing Municipality 400030, China
    Recruiting
    • Wei Zhou, Site 0308 · Contact13883465672
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
    Recruiting
    • Haishan Wu, Site 0245 · Contact8613696834132
  • Cancer Hospital of Shantou University Medical College
    Shantou, Guangdong 515041, China
    Recruiting
    • Wen Lin, Site 0298 · Contact13612388011
  • Peking University Shenzhen Hospital
    Shenzhen, Guangdong 518036, China
    Recruiting
    • Yajie Liu, Site 0919 · Contact13823394075
  • Henan Cancer Hospital
    Zhengzhou, Henan 450008, China
    Recruiting
    • Qiming Wang, Site 0249 · Contact8613783590691
  • Jingzhou First People's Hospital
    Jingzhou, Hubei 0, China
    Recruiting
    • Yonghua Yang, Site 0911 · Contact8618163137331
  • The Central Hospital of Wuhan
    Wuhan, Hubei 430014, China
    Recruiting
    • Hongda Lu, Site 0921 · Contact
  • Local Institution - 0813
    Wuhan, Hubei 430030, China
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0489
    Changsha, Hunan 410031, China
    Not yet recruiting
    • Site 0489 · Contact
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
    Recruiting
    • Songbing Qin, Site 0918 · Contact13771975906
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
    Recruiting
    • Anwen Liu, Site 0254 · Contact8613767120022
  • Local Institution - 0242
    Shenyang, Liaoning 110042, China
    Not yet recruiting
    • Site 0242 · Contact
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710004, China
    Recruiting
    • Hui Guo, Site 0527 · Contact8613572824106
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710061, China
    Recruiting
    • suxia han, Site 0564 · Contact13991822099
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250012, China
    Recruiting
    • Jianbo Wang, Site 0528 · Contact18560081329
  • Shandong Cancer Hospital
    Jinan, Shandong 250117, China
    Recruiting
    • Ligang Xing, Site 0297 · Contact86-15553181309
  • Local Institution - 0248
    Shanghai, Shanghai Municipality 200433, China
    Not yet recruiting
    • Site 0248 · Contact

Showing the first 100 of 259 sites across 32 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Sep 2030, 54 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 54 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2033 → Jan 2034, on Sep 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2026
First posted
Jan 23, 2026
StartActual
Mar 16, 2026
Primary completionEst.
Sep 18, 2030
CompletionEst.
Jan 13, 2034was Dec 2033
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
29 sites added, 29 sites removed. Local Institution - 0217 is now Withdrawn
Show 29 added (6 United States, 5 China, 3 Netherlands, 2 Chile, 2 Germany, 2 Japan, 1 Argentina, 1 Australia, 1 Belgium, 1 Brazil, 1 Bulgaria, 1 Italy, 1 Hungary, 1 India, 1 Singapore)
  • Local Institution - 0935 · Plantation, United States
  • Endeavor Health · Evanston, United States
  • Allina Health Cancer Institute - Abbott Northwestern Hospital · Minneapolis, United States
  • Novant Health Pharmacy Oncology Specialists · Winston-Salem, United States
  • Akron General Medical Center · Akron, United States
  • Investigaciones Oncologicas C Colon SA · Mar del Plata, Argentina
  • Northern Hospital · Epping, Australia
  • Grand Hôpital de Charleroi · Charleroi, Belgium
  • Icesp - Instituto Do Câncer Do Estado de São Paulo · São Paulo, Brazil
  • University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna - ISUL EAD · Sofia, Bulgaria
  • Centro de Oncología de Precisión · Las Condes, Chile
  • Bradfordhill · Santiago, Chile
  • The Second Affiliated Hospital of Xi'an Jiaotong University · Xi'an, China
  • Zhejiang Cancer Hospital · Hangzhou, China
  • Local Institution - 0931 · Berlin, Germany
  • Azienda Ospedaliero Universitaria di Parma · Parma, Italy
  • Radboudumc · Nijmegen, Netherlands
  • Amphia Ziekenhuis, locatie Breda Molengracht · Breda, Netherlands
  • Florida Clinical Trials Group · Tamarac, United States
  • Henan Cancer Hospital · Zhengzhou, China
  • The First Affiliated Hospital of Xi'an Jiaotong University · Xi'an, China
  • West China Hospital, Sichuan University · Chengdu, China
  • Christliches Klinikum Halle (Saale) GmbH · Halle, Germany
  • Farkasgyepui Tudogyogyintezet · Farkasgyepű, Hungary
  • Local Institution - 0864 · Chhatrapati Sambhajinagar, India
  • Aichi Cancer Center Hospital · Nagoya, Japan
  • Tohoku University Hospital · Sendai, Japan
  • Amsterdam UMC, locatie VUmc · Amsterdam, Netherlands
  • Tan Tock Seng Hospital · Singapore, Singapore
Show 29 removed
  • Local Institution - 0780 · Chandler, United States
  • Local Institution - 0850 · Evanston, United States
  • Local Institution - 0142 · Saint Paul, United States
  • Local Institution - 0493 · Winston-Salem, United States
  • Local Institution - 0923 · Akron, United States
  • Local Institution - 0082 · Mar del Plata, Argentina
  • Local Institution - 0458 · Epping, Australia
  • Local Institution - 0111 · Charleroi, Belgium
  • Local Institution - 0912 · São Paulo, Brazil
  • Local Institution - 0732 · Sofia, Bulgaria
  • Local Institution - 0855 · Las Condes, Chile
  • Local Institution - 0077 · Santiago, Chile
  • Local Institution - 0527 · Xi'an, China
  • Local Institution - 0301 · Hangzhou, China
  • Local Institution - 0390 · Parma, Italy
  • Local Institution - 0243 · Nijmegen, Netherlands
  • Local Institution - 0095 · Breda, Netherlands
  • Local Institution - 0935 · Plantation, United States
  • Local Institution - 0249 · Zhengzhou, China
  • Local Institution - 0564 · Xi'an, China
  • Local Institution - 0440 · Chengdu, China
  • Krankenhaus Martha-Maria Halle-Doelau Ggmbh · Haile, Germany
  • Local Institution - 0776 · Farkasgyepű, Hungary
  • Local Institution - 0864 · Aurangabad, India
  • Local Institution - 0663 · Mumbai, India
  • Local Institution - 0014 · Nagoya, Japan
  • Local Institution - 0759 · Sendai, Japan
  • Local Institution - 0091 · Amsterdam, Netherlands
  • Local Institution - 0647 · Singapore, Singapore
across 2 updates, Sep 30, 2026 – Nov 5, 2026
Study completion
Dec 31, 2033→Jan 13, 2034
Sep 30, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Local Institution - 0217 · Berlin, GermanyContact removed (no phone or email listed)
  • Kitasato University Hospital · Sagamihara, JapanContact •••3533→•••8111
  • Saitama Medical University International Medical Center · Hidaka, JapanContact •••7189→•••4111
across 2 updates, Sep 30, 2026 – Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    11 sites added, 12 sites removed
    Show 11 added (3 China, 2 Japan, 1 United States, 1 Germany, 1 Hungary, 1 India, 1 Netherlands, 1 Singapore)
    • Florida Clinical Trials Group · Tamarac, United States
    • Henan Cancer Hospital · Zhengzhou, China
    • The First Affiliated Hospital of Xi'an Jiaotong University · Xi'an, China
    • West China Hospital, Sichuan University · Chengdu, China
    • Christliches Klinikum Halle (Saale) GmbH · Halle, Germany
    • Farkasgyepui Tudogyogyintezet · Farkasgyepű, Hungary
    • Local Institution - 0864 · Chhatrapati Sambhajinagar, India
    • Aichi Cancer Center Hospital · Nagoya, Japan
    • Tohoku University Hospital · Sendai, Japan
    • Amsterdam UMC, locatie VUmc · Amsterdam, Netherlands
    • Tan Tock Seng Hospital · Singapore, Singapore
    Show 12 removed
    • Local Institution - 0935 · Plantation, United States
    • Local Institution - 0249 · Zhengzhou, China
    • Local Institution - 0564 · Xi'an, China
    • Local Institution - 0440 · Chengdu, China
    • Krankenhaus Martha-Maria Halle-Doelau Ggmbh · Haile, Germany
    • Local Institution - 0776 · Farkasgyepű, Hungary
    • Local Institution - 0864 · Aurangabad, India
    • Local Institution - 0663 · Mumbai, India
    • Local Institution - 0014 · Nagoya, Japan
    • Local Institution - 0759 · Sendai, Japan
    • Local Institution - 0091 · Amsterdam, Netherlands
    • Local Institution - 0647 · Singapore, Singapore
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Kitasato University Hospital · Sagamihara, JapanContact •••3533→•••8111
    • Saitama Medical University International Medical Center · Hidaka, JapanContact •••7189→•••4111
    + 1 other change: verification date
  2. Sep 30, 2026
    18 sites added, 17 sites removed. Local Institution - 0217 is now Withdrawn
    Show 18 added (5 United States, 2 Chile, 2 China, 2 Netherlands, 1 Argentina, 1 Australia, 1 Belgium, 1 Brazil, 1 Bulgaria, 1 Germany, 1 Italy)
    • Local Institution - 0935 · Plantation, United States
    • Endeavor Health · Evanston, United States
    • Allina Health Cancer Institute - Abbott Northwestern Hospital · Minneapolis, United States
    • Novant Health Pharmacy Oncology Specialists · Winston-Salem, United States
    • Akron General Medical Center · Akron, United States
    • Investigaciones Oncologicas C Colon SA · Mar del Plata, Argentina
    • Northern Hospital · Epping, Australia
    • Grand Hôpital de Charleroi · Charleroi, Belgium
    • Icesp - Instituto Do Câncer Do Estado de São Paulo · São Paulo, Brazil
    • University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna - ISUL EAD · Sofia, Bulgaria
    • Centro de Oncología de Precisión · Las Condes, Chile
    • Bradfordhill · Santiago, Chile
    • The Second Affiliated Hospital of Xi'an Jiaotong University · Xi'an, China
    • Zhejiang Cancer Hospital · Hangzhou, China
    • Local Institution - 0931 · Berlin, Germany
    • Azienda Ospedaliero Universitaria di Parma · Parma, Italy
    • Radboudumc · Nijmegen, Netherlands
    • Amphia Ziekenhuis, locatie Breda Molengracht · Breda, Netherlands
    Show 17 removed
    • Local Institution - 0780 · Chandler, United States
    • Local Institution - 0850 · Evanston, United States
    • Local Institution - 0142 · Saint Paul, United States
    • Local Institution - 0493 · Winston-Salem, United States
    • Local Institution - 0923 · Akron, United States
    • Local Institution - 0082 · Mar del Plata, Argentina
    • Local Institution - 0458 · Epping, Australia
    • Local Institution - 0111 · Charleroi, Belgium
    • Local Institution - 0912 · São Paulo, Brazil
    • Local Institution - 0732 · Sofia, Bulgaria
    • Local Institution - 0855 · Las Condes, Chile
    • Local Institution - 0077 · Santiago, Chile
    • Local Institution - 0527 · Xi'an, China
    • Local Institution - 0301 · Hangzhou, China
    • Local Institution - 0390 · Parma, Italy
    • Local Institution - 0243 · Nijmegen, Netherlands
    • Local Institution - 0095 · Breda, Netherlands
    Study completion Dec 31, 2033→Jan 13, 2034
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Local Institution - 0217 · Berlin, GermanyContact removed (no phone or email listed)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07361497
Collaborators
BioNTech SE
Responsible party
Sponsor
First posted
Jan 23, 2026
Start date
Mar 16, 2026
Primary completion
Sep 18, 2030 (estimated)
Completion
Jan 13, 2034 (estimated)
Last update
Nov 5, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pumitamig

Start the discussion